ilmscore | Prediction Details
"While promising lateage candidates in lung and bladder cancer could reshape standard of care by 2026 and beyond."
By Millionaires Investment Secrets | July 25, 2025 | Pending
From video
What If Wall Street's Got It All Wrong?? Howard Marks Thesis Points To 3 Overlooked Stocks - 00:05:03 - 00:05:08
Interpreted Prediction
Pfizer's promising late-stage lung and bladder cancer drug candidates are predicted to potentially reshape standard of care by 2026 and beyond.

Prediction Details

Ticker
PFE
Initial Price
24.79 USD

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.